Capital International Sarl Has $18.01 Million Stock Position in Pfizer Inc. $PFE

Capital International Sarl grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 72.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 723,079 shares of the biopharmaceutical company’s stock after buying an additional 304,464 shares during the quarter. Capital International Sarl’s holdings in Pfizer were worth $18,005,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Capital International Ltd. CA raised its holdings in shares of Pfizer by 58.4% during the fourth quarter. Capital International Ltd. CA now owns 417,499 shares of the biopharmaceutical company’s stock valued at $10,396,000 after purchasing an additional 154,008 shares during the period. Capital International Inc. CA raised its holdings in shares of Pfizer by 182.3% during the fourth quarter. Capital International Inc. CA now owns 353,156 shares of the biopharmaceutical company’s stock valued at $8,794,000 after purchasing an additional 228,051 shares during the period. Capital Group Investment Management PTE. LTD. raised its holdings in shares of Pfizer by 61.0% during the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 91,660 shares of the biopharmaceutical company’s stock valued at $2,282,000 after purchasing an additional 34,716 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Pfizer by 8.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 1,467,783 shares of the biopharmaceutical company’s stock valued at $35,652,000 after purchasing an additional 109,881 shares during the period. Finally, Modus Advisors LLC acquired a new stake in shares of Pfizer in the 4th quarter worth about $45,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.4%

Shares of PFE stock opened at $26.04 on Friday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a 50-day simple moving average of $26.62 and a two-hundred day simple moving average of $26.29. The company has a market capitalization of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the firm posted $0.92 EPS. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Barclays began coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. Finally, Guggenheim upped their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.